We actively collaborate with referring providers who wish to enroll patients diagnosed with clonal cytopenia of undetermined significance (CCUS) in the PIMMs clinical trial. We also welcome inquiries from physicians who would like to serve as a site investigator/participating site for the PIMMs clinical trial.
Potential patients will have had unexplained low blood cell counts for at least six months and must carry a mutation in the gene IDH1 (R132).
In addition, we require the following to determine eligibility for the study:
- Physical exam/Medical history
- Blood tests to check blood counts and organ function and confirm presence of
- IDH1 (R132) gene mutation
- Urine/blood test to rule out pregnancy
- Electrocardiogram
- Bone marrow biopsy and aspiration
If some of the tests above have been performed recently, they may not need to be repeated. You and your patient will work directly with the study investigator to determine what is needed to confirm or rule out eligibility.
Depending upon proximity to a participating site, your patient has the option to:
- Travel to a participating site; or
- Enroll remotely with all study activities and lab tests coordinated locally by an oncologist
As CCUS places patients at high risk for later development of acute myeloid leukemia or myelodysplastic syndrome, we encourage you to consider enrolling your patient in this study.
To Enroll Your Patient or Become a Participating Site
To start the patient eligibility and enrollment process or request information about becoming a participating site, please call (314) 747-3543 or email us.
Coordinating Center/Principal Investigator
Siteman Cancer Center at Washington University School of Medicine/Barnes-Jewish Hospital in St. Louis, MO, serves as the coordinating center for the PIMMs clinical trial.
Principal investigator for the study is Kelly Bolton, MD, PhD.